Artemisinin-based combination therapy for ... - The Cochrane Library

(Continued)
Efficacy: Total Failure
(P. falciparum)
Day 42 PCR adjusted
- Asia
Efficacy: Total Failure
(P. falciparum)
Day 42 PCR unadjusted
- Asia
Vivax efficacy: P.
vivax parasitaemia
by D42
Transmission
potential: Gametocytedevelopment
(in those negative
at baseline)
Harms: Serious adverse
events (including
deaths)
Harms: Early vomiting
22 per 1000 17 per 1000
(4 to 83)
161 per 1000 97 per 1000
(56 to 169)
197 per 1000 63 per 1000
(47 to 85)
RR 0.77
(0.16 to 3.76)
RR 0.60
(0.35 to 1.05)
RR 0.32
(0.24 to 0.43)
317
(1)
356
(1)
1442
(4)
- - - 1203
(4)
6 per 1000 10 per 1000
(4 to 27)
23 per 1000 32 per 1000
(16 to 64)
RR 1.71
(0.66 to 4.46)
RR 1.38
(0.68 to 2.78)
2110
(5)
1147
(2)
⊕
very low 1,10,11,12,13
⊕⊕
low 10,11,12,14
⊕⊕⊕⊕
high 2,5,7,15,16
⊕
very low 17,18,19
⊕⊕
low 5,20,21
⊕
very low 5,21,22
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
243